In vivo studies using animal models or patient‐derived samples would provide a more comprehensive understanding of the therapeutic potential of SOX18 inhibition in lymphangiosarcoma treatment and its effects on tumor growth, metastasis, and overall survival. This evidence concerns the gene SOX18 and lymphangiosarcoma.